print_label | resize_label

A TREATMENT FOR ADULTS WITH TYPE 2 DIABETES MELLITUS, IN ADDITION TO DIET AND EXERCISE

FORMULARY COVERAGE FOR ONGLYZA

FORMULARY FINDER

Formulary Finder

Formulary Search

Brand: {Brand_Name}
State: Selection
County (optional): Selection
Plan Type: Selection

Please select a state and county (optional) to find formulary information for {Brand_Name}. You can review tier status and managed care coverage for commercial, Medicare, and Medicaid plans.

Selected Plans for {Brand_Name}

Reset selections

Change Plans

{Brand_Name}^®
({Generic_Name})

Tier 1 = lowest copay; Tier 2 = middle-level copay (preferred); Tier 3-7 = higher-level copay (non-preferred); For Medicare Part D plans, 'Preferred - Tier 3' refers to the lowest copay level for branded products; NC = not covered; NA = data not available; PA = prior authorization; QL = quantity limits; ST = step therapy; OR = other restrictions

Individual costs and benefit design may vary. Please consult with individual plans for specific information.

AstraZeneca does not endorse any individual, commercial, Medicare Part D, or Medicaid plan or plans.

Medications listed in the "Other Products" menu are provided by Fingertip Formulary^®. All registered trademarks are registered to their respective companies and are not licensed or manufactured by AstraZeneca.

Source: Fingertip Formulary^® Database. Mar 10, 2019.

Ajax error

JavaScript is required to access [Dynamic Service Title]

Please enable JavaScript in your browser settings.

Back to Home

Formulary Finder

State:

County:

Please select a state to find formulary information for {Brand_Name}, and select products in the same class. You can review tier status and managed care coverage for commercial, Medicare, and Medicaid plans.

Ajax error

Money-Saving Offers for Your Patients

With the Savings Card your commercially insured patients may pay as low as $0* for as long as you prescribe ONGLYZA. Learn more

*As low as $0 for as long as you prescribe any available dose of ONGLYZA. No activation required. Subject to eligibility. Restrictions apply. Not available for government-insured patients.

IMPORTANT SAFETY INFORMATION

Important Safety Information for ONGLYZA

Contraindications

Prior serious hypersensitivity reaction to ONGLYZA

Warnings and Precautions

Pancreatitis: There have been postmarketing reports of acute pancreatitis in patients taking ONGLYZA, and in the SAVOR cardiovascular outcomes trial. Observe for pancreatitis. If pancreatitis is suspected, discontinue ONGLYZA.

Heart Failure: In the SAVOR cardiovascular outcomes trial, more patients treated with ONGLYZA were hospitalized for heart failure compared to placebo. Patients with a prior history of heart failure or renal impairment had a higher risk for hospitalization for heart failure. Consider the risks and benefits of ONGLYZA in patients who have known risk factors for heart failure. Monitor for signs and symptoms. If heart failure develops, consider discontinuation of ONGLYZA.

Hypoglycemia: When ONGLYZA was used in combination with a sulfonylurea or with insulin, the incidence of confirmed hypoglycemia was increased over that of placebo. Consider lowering the dose of these agents when coadministered with ONGLYZA.

Hypersensitivity Reactions: Serious reactions have been reported in patients treated with ONGLYZA, including anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with ONGLYZA, with some reports occurring after the first dose. If a serious hypersensitivity reaction is suspected, discontinue ONGLYZA. Use caution in patients with a history of angioedema to another DPP-4 inhibitor.

Severe and Disabling Arthralgia has been reported in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider discontinuing drug if appropriate.

Bullous Pemphigoid: There have been postmarketing reports of bullous pemphigoid requiring hospitalization in patients taking DPP-4 inhibitors. Tell patients to report development of blisters or erosions. If suspected, discontinue ONGLYZA.

Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA.

Most Common Adverse Reactions

Most common adverse reactions reported in ≥5% of patients treated with ONGLYZA and more commonly than in patients treated with placebo were upper respiratory tract infection (7.7%, 7.6%), urinary tract infection (6.8%, 6.1%), and headache (6.5%, 5.9%).

Peripheral edema was reported more commonly in patients treated with the combination of ONGLYZA 5 mg and a thiazolidinedione (TZD) than in patients treated with the combination of placebo and TZD (8.1% vs 4.3%, respectively).

Drug Interactions

Strong CYP3A4/5 inhibitors (eg, ketoconazole): Coadministration with ONGLYZA significantly increases saxagliptin concentrations. Recommend limiting ONGLYZA dosage to 2.5 mg once daily.

Use in Specific Populations

In patients with moderate or severe renal impairment, or end-stage renal disease (eGFR <45 mL/min/1.73 m²), recommended dosage is 2.5 mg once daily regardless of meals. ONGLYZA should be administered following hemodialysis. Assess renal function before starting ONGLYZA and periodically thereafter.

Indication and Limitations of Use

ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

ONGLYZA is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Please see US Full Prescribing Information and Medication Guide for ONGLYZA.

You may report side effects related to AstraZeneca products by clicking here.